By Stephen Nakrosis

 

Shares of Marker Therapeutics Inc. were trading higher Friday, continuing momentum from the after-hours market Thursday following news the U.S. Food and Drug Administration approved the company's investigational new drug application for MT-601 to treat certain patients with non-Hodgkin lymphoma.

At 11:26 a.m. ET, the company's stock had risen 55% to trade at 51 on Nasdaq. Volume at the time topped 51.1 million shares, above the stock's 65-day average volume of 373,289 shares.

Following the news of the FDA approval Thursday, Marker shares rose in the late-trading market. The stock closed Thursday's regular session at 33 cents and opened at 60 cents on Friday.

Peter Hoang, the company's president and chief executive, said: "FDA clearance of our IND for MT-601 is a significant milestone as we advance our pipeline in a number of company-sponsored trials." He said that MT-601 targets six tumor-associated antigens highly expressed in lymphoma, and Marker looks plans to initiate a company-sponsored Phase 1 study next year.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

August 05, 2022 11:49 ET (15:49 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Marker Therapeutics Charts.
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Marker Therapeutics Charts.